FDA Issues Draft Guidance on Expedited Programs for Regenerative Medicine

Published on Holland & Knight

The FDA has released new draft guidance outlining expedited pathways for regenerative medicine therapies. It clarifies RMAT eligibility, flexible trial designs, and long-term safety monitoring while encouraging use of real-world evidence and digital health tools. Sponsors are urged to submit feedback before the November 24, 2025 deadline.

👉 Read the full article: FDA Publishes New Draft Guidance on Regenerative Medicine Therapies

Disclaimer

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link. SSCTR does not provide medical advice, and the views expressed are for educational purposes only.